Answers are grounded in this paper and cite their sources.
A sudden increase in the incidence of post-transplantation lymphoproliferative disorder among the patients in our cardiac-transplantation program was temporally related to introduction of the immunosuppressive drug OKT3. This monoclonal antibody has come to be widely used in recent years both to prevent and to treat rejection after cardiac transplantation.
No takes yet. Share an insight, caveat, or question.
Swinnen et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: